

Assay for Quantitative Analysis of Losartan Potassium by using UV Spectroscopy

Zehra Ashraf¹, Nimra Waheed² and Zehra Ashraf³

¹ Faculty of Pharmacy Jinnah University for Women, Karachi.

Received: 15 April 2015 Accepted: 3 May 2015 Published: 15 May 2015

Abstract

Drug is a substance that brings about a change in the biological functions through its chemical actions. Drug losartan are the first marketed beta blockers of the angiotensin II-type (AT1) receptor. It is the prototypic ARB. Their pharmacologic effect are very similar to the ACE inhibitors, because they also produce the arteriolar and venous dilation and block aldosterone secretion, thus lowers the blood pressure, decreases the salt and water retention. Its chemical name is losartan potassium. It is indicated in mild to severe hypertension and contraindicated in pregnancy because it increases teratogenic risk and may leads to mal formation or death of fetus. It is light yellow solid and stable under recommended storage conditions, freely soluble in water and soluble in alcohol. Losartan inhibit the binding of angiotensin II to type 1 in tissue (kidney and adrenal gland) losartan and its active metabolite is more potent then losartan inhabitation causes vasodilation and decreases sodium and water retention. The aim of study is to determine the

Index terms— losartan potassium, anti-hypertensive, beta blockers.

1 I. Introduction

rug is a substance that brings about a change in the biological functions through its chemical actions. Losartan are the first marketed blockers of the angiotensin II-type receptor (non peptide, orally active, and competitive antagonist of AT1 receptor) [1]. Its wavelength is 234nm which lies in the UV range i.e. 200-380nm. It is the prototypic ARB. Their pharmacologic effects are very similar to the ACE inhibitors, because they also produce the arteriolar and venous dilation and block aldosterone secretion, thus lower the blood pressure, decreases the salt and water retention. They have no effect on bradykinin levels and metabolism [2]. They decrease the nephrotoxicity of diabetes and making attractive therapy in hypertensive diabetics. They also provide benefit in patient with heart failure and chronic kidney disease. The adverse effects are also similar to ACE's inhibitors, but the risk of cough and angioedema is decreased because it has no effect on bradykinin levels ARB's are fetotoxic and should not be used by women who are pregnant, it is contraindicated during pregnancy [3].

Losartan belong to antihypertensive therapeutic class. It blocks the receptor also called angiotensin II receptor blocker (ARBs). Losartan is specific or selective type I angiotensin II receptor (AT1) antagonist. They block receptor as a result decrease in blood pressure (rennin-angiotensin-aldosterone system) RAAS [4].

Losartan inhibit the binding of angiotensin II to type I in tissue (kidney and adrenal glands). Losartan and its active metabolites E-3174 is more potent then losartan inhibition (angiotensin II to type I) cause vasodilation (normally AT1?vasoconstriction + aldosterone) decrease sodium and water retention and increases excretion [5].

The formula of losartan is C₂₂ H₂₃ ClKN₆O. Losartan is given orally and it is well absorbed but undergo first pass metabolism. Systemic bioavailability is 33 after metabolism it is highly protein bound and while taking the food with medicine decreases its absorption. In healthy individual it distributes about 34l and its metabolite about 12l. It is metabolized in liver by an enzyme CYP450, 2C9 and 3A4 and converts into an active metabolite 5 carboxylic acid derivatives (E-3174). It is administered orally so 35% excreted in urine and about 60% excretion

in feces. When administer by IV route then 45% of drug is excreted in urine and 50% drug in feces [6]. Protein binding of losartan is 99.7% (primarily albumin) and bioavailability is 25-35%. [7].

The appearance of losartan potassium is white to off white crystalline powder its melting point is between 263-265C and it is freely soluble in water. Molecular mass of losartan potassium is 462.01 [8].

Its indications are: mild to severe hypertension, diabetic nephropathy reducing risk of stroke in people with heart disease [9]. Its adverse effect include: losartan worsens the condition the patients who had a history of PD, in the form of several falls and episodes of freezing and severe bradykinesia. So, its combination with levodopa or carbidopa should be avoided [10]. Hypergranulosis and hyperkeratosis be developed during its treatment with losartan for arterial hypertension. Long term of losartan potassium develops angioedema. It triggers psoriasis and generalized bullous lesions and patients can develop Steven-Johnson syndrome and renal impairment during the treatment of hypertension with losartan [11].

Losartan potassium is contraindicated in pregnancy because it is fetotoxic and can cause mal formation of the fetus and even leads to death and it is also contraindicated for renal impaired function and bilateral renal artery stenosis [12].

Drug-Drug interactions of losartan potassium with fluconazole rises the plasma level of losartan, indomethacin blunt its antihypertensive effect, concomitant use of potassium supplement may lead to increase in serum potassium, rifampicin may reduce the antihypertensive effect, and increase in lithium may increase its adverse effects [13]. Drug food interactions of losartan potassium with grapefruit which decreases its active metabolites so reducing the efficacy, drinking alcohol can further lower B.P and may increase certain side effects [14]

2 II. Methodology a) Material

Distilled water, losartan potassium tablets standard and sample, glass rod, mortar and pestle, measuring cylinder, tissue paper, weigh balance and UV visible spectrophotometer.

3 b) Method

? Wash the apparatus (beakers, glass rod, conical flask, mortar and pestle, measuring cylinder) and rinsed with freshly prepared distilled water. Dry all the apparatus. Now weight the tablets accurately. Crush the tablets in mortar and pestle. Transfer the 0.2mg of calculated amount of drug into 100ml of beaker and make up the volume with freshly prepared distilled water. Note down the absorbance of standard solution and sample solution separately at 234nm wavelength by using UV visible spectrophotometer.

? Calculate the % assay with the help of formula [15]. Each tablet of 100mg or 0.1gm
—————0.175gm 0.1gm —————0.2475gm 0.2gm ————— $0.157 \times 0.1 / 2 = 0.314$ gm 0.2gm ————— 0.2475×0.1
Losartan potassium

4 III.

5 Observations and Calculations

6 Standard

7 IV. Result

We have performed the assay of losartan potassium by using UV visible spectrophotometer, and the calculated % assay of losartan potassium is 98% [16].

8 V. Discussion

The aim of the study was to carry out the pharmaceutical assay on different brands of losartan potassium by using spectrophotometer. This results shows that absorbance is directly proportional to concentration so, it obeys Beer's Lambert law and assay of all brands are within range of USP and British pharmacopeia linearity given in figure 1. We have done these types of assay for different brand which helpful for selecting drugs [17].¹



Figure 1:

[Barry et al.] , M Barry , M D Brenner , E Mark , M D Cooper , D Ph , M D Dick De Zeeuw , D Ph , F William .

[Sica (2005)] , Domenic A Sica . *Clinical Pharmacokinetics of Losartan* August 2005. 44 (8) p. . (Clinical Pharmacokinetics)

[George and Pylypchuk (1998)] , B George , Pylypchuk . *ACE Inhibitor-Versus Angiotensin II Blocker-Induced Cough and Angioedema* October 1998. 32 p. . (Annal of Pharmacotherapy.)

[Goa and Wagstaff (1996)] ‘A Review of its Pharmacology, Clinical Efficacy and Tolerability in the Management of Hypertension’. Karen L Goa , Antona J Wagstaff . *Drugs* May 1996. 51 (5) p. .

[Goa and Wagstaff (1996)] ‘A Review of its Pharmacology, Clinical Efficacy and Tolerability in the Management of Hypertension’. Karen L Goa , Antona J Wagstaff . *Drugs* May 1996. 51 (5) p. .

[Alwan et al. (2005)] *Angiotensin II receptor antagonist treatment during pregnancy, Clinical and Molecular Teratology*, S Alwan , * , J E Polifka , J M Friedman . 10.1002/bdra.v73:2/issuetoc. February 2005. 73 p. .

[Hernández-Hernández (2014)] *Angiotensin II receptor antagonists role in arterial hypertension*, Rafael Hernández-Hernández . Apr 27. 2014.

[Naveed et al. ()] ‘Assay of Pioglitazone HCL by Using UV Visible Spectrophotometer’. Safila Naveed , Zehra Ashraf , Tasleem Mukhtar . *British Journal of Research* 2015. p. .

[Katzung et al. ()] *Basic and clinical pharmacology*, B G Katzung , S B Masters , A Trevor . 2012. p. 185. (antihypertensive agent. Lange medical publications, e (12 th)

[Nafisur Rahman, Masoom Raza Siddiqui and Syed Najmul Hejaz Azmi (2006)] ‘Development and Validation of Kinetic Spectrophotometric Method for the Determination of Losartan Potassium in Pure and Commercial Tablets’. *Journal of the Chinese Chemical Society* Nafisur Rahman, Masoom Raza Siddiqui and Syed Najmul Hejaz Azmi (ed.) June 2006. p. .

[Yoshinaga ()] ‘Drug-interactions and adverse effects of losartan potassium, an angiotensin II receptor antagonist’. K Yoshinaga . *Japanese Journal of Clinical Medicine* 1999. 57 (5) p. .

[Keane (2001)] ‘Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy’. M Keane . *The New England Journal of Medicine* Sep 2001. 345 p. .

[Shanmugam et al. (2011)] ‘Formulation and Evaluation of Sustained Release Matrix Tablets of Losartan potassium’. S Shanmugam , Ramya Chakrahari , * , K Sundaramoorthy , T Ayyappan , T Vetrichelvan . *International Journal of PharmTech Research* Mar 2011. 3 (1) p. .

[Clark et al. (ed.) ()] *Lippincott’s illustrated reviews pharmacology*, M A Clark , R Finkel , J A Rey , Whalen K . Lippincott Williams and Wilkins (ed.) 2012. 228 p. 236. (antihypertensive. wolters kluwer business. Edition (5 th)

[Kirk (1999)] ‘Pharm-d, wake forest university school of medicine’. Julienne K Kirk . *Amfam physician* June 1999. 59 p. . (II)

[Boersma et al. ()] ‘pharmacoeconomics of angiotensin II antagonist in type 2 diabetic patients with nephropathy”: implications for decision making’. C Boersma , . J Atthobari , R Gansevoort , De Jongvan Den Berg , L De Jong , P De Zeevw , D Etal . *Pharmacoeconomics*” 2006. 24 (6) p. .

[US] Guidelines Handbook Global Journals Inc ()] ‘US) Guidelines Handbook’. www.GlobalJournals.org Global Journals Inc 2015.

[Zehra ashraf and Muhammad tanweer alam, using UV spectrophotometric method to determine the linearity of vildagliptin brand]

‘Zehra ashraf and Muhammad tanweer alam, using UV spectrophotometric method to determine the linearity of vildagliptin brands’. *Safila naveed*, 2015.

[Zehra ashraf and Tasleem mukhtar, assay of different brands of cefadroxil by using spectrophotometric method Safila naveed ()]

‘Zehra ashraf and Tasleem mukhtar, assay of different brands of cefadroxil by using spectrophotometric method’. *Safila naveed*, 2015. 14.